US FDA panel votes against use of Medtronic's blood pressure treatment device
23/08/2023 23:06
Aug 23 (Reuters) - The U.S. Food and Drug
Administration's independent experts on Wednesday narrowly voted
against recommending the approval of Medtronic's blood pressure
treatment device, saying risks tied to using it do not outweigh
the benefits.
The same panel on Tuesday voted in favor of rival ReCor's
device for use in a surgery called renal denervation in patients
whose high blood pressure cannot be controlled by drugs.
(Reporting by Sriparna Roy in Bengaluru; Editing by Krishna
Chandra Eluri)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug